Antigenics, Inc. (Pennsylvania) engages in the development of pharmaceutical products for cancer treatment. The company is headquartered in Horsham, Pennsylvania and currently employs 29 full-time employees. The company went IPO on 2001-07-18. The firm is developing a series of checkpoint modulators (CPM) for the treatment of patients with cancer, infectious diseases, and other immune disorders; heat shock protein (HSP)-based vaccines, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Retrocyte Display (Retroviral B Lymphocyte Display) is an antibody discovery platform designed for the discovery and optimization of fully human and humanized monoclonal antibodies against an array of molecular targets. Its HSP-based vaccine platform includes its Prophage Series vaccine candidates for the treatment of cancer and its HerpV vaccine candidate for the treatment of genital herpes. Its pipeline of product candidates containing QS-21 Stimulon includes vaccines for infectious diseases, cancer types and Alzheimer's disease.
Follow-Up Questions
What is Antigenics Inc (ANTI)'s P/E Ratio?
The P/E ratio of Antigenics Inc is 0
Who is the CEO of Antigenics Inc?
DR. Geoffrey Cox is the Chairman of the Board of Antigenics Inc, joining the firm since 1997.
What is the price performance of ANTI stock?
The current price of ANTI is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Antigenics Inc?
Antigenics Inc belongs to N/A industry and the sector is N/A
